Following a successful trading update, our CEO, Martin Gouldstone, spoke with Steve Darling from Proactive to discuss Oncimmune’s recent commercial progress. Over the past quarter, we’ve maintained strong momentum, signing three new contracts valued at £0.34 million. This brings our total to eight contracts, worth £2.14 million, secured in just three months.
Two of these recent agreements represent a significant expansion, with work in new areas for an existing top 10 global pharmaceutical partner. This collaboration highlights Oncimmune’s versatility and growing value to leading industry players. The third contract taps into our expertise in profiling Immunoglobulin type E (IgE) autoantibodies, further solidifying our relationship with another top-tier pharmaceutical client.
While these contracts do not lead to an increase in our FY2025 revenue outlook, they reinforce our position to meet market expectations. We now have visibility on over 40% of our FY2025 revenue target of £6.9 million, underpinned by a robust and high-confidence pipeline. This continued success underscores Oncimmune’s expanding commercial traction and our role as a trusted partner to pharmaceutical companies globally.